Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin
2020-02-03 · Moleculin Biotech, Inc. · original moleculin.com ↗
HOUSTON, Feb. 3, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that its open label, single arm US Phase 1 trial met its primary objective of demonstrating the safety of Liposomal Annamycin (“Annamycin”) in treating relapsed or refractory acute myeloid leukemia (“AML”). The Company also announced an update on interim enrollment, safety and efficacy data in its parallel Phase 1 trial in Europe, which continues with dose escalation, thus far without safety concerns.
The release as fetched from its publisher. moleculin.com ↗